Dongyangguang Changjiang Pharmaceutical (01558) is now up more than 3%. As of press release, it is up 3.15% to HK$12.46, with a turnover of HK$18.895 million.
The Zhitong Finance App learned that Dongyang Changjiang Pharmaceutical (01558) is now up more than 3%. As of press release, it has risen 3.15% to HK$12.46, with a turnover of HK$18.895 million.
According to the news, the National Health Insurance Administration recently organized all provinces across the country to continue procurement after the expiration of the insulin collection agreement, and opened a tender in Shanghai on April 23. The industry generally believes that the pricing for this succession of insulin purchases is relatively moderate. According to the proposed selection results, Dongyangguang Changjiang Pharmaceutical has 5 products to win the bid.
Guoxin Securities pointed out that domestic insulin companies are expected to maintain the main stock market through reasonable price cuts and seek the release of new products through collection. Considering that the current round of continuous procurement rules are relatively moderate, it is expected that price changes will disrupt short-term performance less than the initial national procurement. It is recommended to actively pay attention to the selection of relevant companies in this round of procurement.